Fractional flow reserve: current status

A.V. Khokhlov, M.V. Shymanko, M.V. Stan

References  

 1. Adjedj J, Toth GG, Johnson NP, Pellicano M, Ferrara A, Floré V, Di Gioia G, Barbato E, Muller O, De Bruyne B. Intracoronary Adenosine: Dose-Response Relationship With Hyperemia. JACC. Cardiovasc Interv. 2015;8:1422–1430. doi: 10.1016/j.jcin.2015.04.028.

2. Ahn JM, Park DW, Shin ES, Koo BK, Nam CW, Doh JH, Kim JH, Chae IH, Yoon JH, Her SH, Seung KB, Chung WY, Yoo SY, Lee JB, Choi SW, Park K, Hong TJ, Lee SY, Han M, Lee PH, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park SJ; IRIS-FFR Investigators. Fractional Flow Reserve and Cardiac Events in Coronary Artery Disease: Data From a Prospective Registry. Circulation. 2017;29 [Epub ahead of print]. doi: 10.1161/circulationaha.117.030551.
3. Bech GJ, De Bruyne B, Pijls NH,de Muinck ED, Hoorntje JCA, Escaned J, Stella PR, Boersma E, Bartunek J, Koolen JJ, Wijns W. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation. 2001;103:2928–2934. doi: 10.1161/01.cir.103.24.2928.
4. Christou MA, Siontis GC, Katritsis DG, Ioannidis JP. Meta-analysis of fractional flow reserve versus quantitative coronary angiography and noninvasive imaging for evaluation of myocardial ischemia. Am J Cardiol. 2007;99:450–456. doi: 10.1016/j.amjcard.2006.09.092.
5. Curzen N, Rana O, Nicholas Z, Golledge P, Zaman A, Oldroyd K, Hanratty C, Banning A, Wheatcroft S, Hobson A, Chitkara K, Hildick-Smith D, McKenzie D, Calver A, Dimitrov BD, Corbett S.. Does routine pressure wire assessment influence management strategy at coronary angiography for diagnosis of chest pain?: the RIPCORD study. Circ Cardiovasc Interv. 2014;7:248–255. doi: 10.1161/circoutcomes.117.004191.
6. Dattilo PB, Prasad A, Honeycutt E, Wang TY, Messenger JC. Contemporary patterns of fractional flow reserve and intravascular ultrasound use among patients undergoing percutaneous coronary intervention in the United States: insights from the National Cardiovascular Data Registry. J Am Coll Cardiol. 2012;60:2337–2339. doi: 10.1016/j.jacc.2012.08.990.
7. Davies JE, Sen S, Dehbi HM, Al-Lamee R, Petraco R, Nijjer SS, Bhindi R, Lehman SJ, Walters D, Sapontis J, Janssens L, Vrints CJ, Khashaba A, Laine M, Van Belle E, Krackhardt F, Bojara W, Going O, Härle T, Indolfi C, Niccoli G, Ribichini F, Tanaka N, Yokoi H, Takashima H, Kikuta Y, Erglis A, Vinhas H, Canas Silva P, Baptista SB, Alghamdi A, Hellig F, Koo BK, Nam CW, Shin ES, Doh JH, Brugaletta S, Alegria-Barrero E, Meuwissen M, Piek JJ, van Royen N, Sezer M, Di Mario C, Gerber RT, Malik IS, Sharp ASP, Talwar S, Tang K, Samady H, Altman J, Seto AH, Singh J, Jeremias A, Matsuo H, Kharbanda RK, Patel MR, Serruys P, Escaned J. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. New Engl J Med. 2017;376:1824–1834. doi: 10.1056/nejmc1711333.
8. De Bruyne B, Baudhuin T, Melin JA, Pijls NH, Sys SU, Bol A, Paulus WJ, Heyndrickx GR, Wijns W. Coronary flow reserve calculated from pressure measurements in humans. Validation with positron emission tomography. Circulation. 1994;89:1013–1022. doi: 10.1161/01.CIR.89.3.1013.
9. De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, Jagic N, Mobius-Winckler S, Rioufol G, Witt N, Kala P, MacCarthy P et al., for the FAME 2 Trial Investigators*. Fractional flow reserve-guided PCI for stable coronary artery disease. New Engl J Med. 2014;371:1208–1217. doi: 10.1056/nejmx140052.
10. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PAL, Piroth Z, Jagic N, Möbius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, et al., for the FAME 2 Trial Investigators*. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. New Engl J Med. 2012;367:991–1001. doi: 10.1056/nejmx120078.
11. Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, Jørgensen E, Pedersen F, Saunamäki K, Clemmensen P, De Backer O, Ravkilde J, Tilsted HH, Villadsen AB, Aarøe J, Jensen SE, Raungaard B, Køber L; DANAMI-3—PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3 – PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015;386:665–671. doi: 10.3410/f.725787766.793509725.
12. Götberg M, Christiansen EH, Gudmundsdottir IJ, Sandhall L, Danielewicz M, Jakobsen L, Olsson S-E, Öhagen P, Olsson H, Omerovic E, Calais F, Lindroos P, et al., for the iFR-SWEDEHEART Investigators. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. New Engl J Med. 2017;376:1813–1823. doi: 10.3410/f.727423277.793532843.
13. Hakeem A, Edupuganti MM, Almomani A. et al. Long-Term Prognosis of Deferred Acute Coronary Syndrome Lesions Based on Nonischemic Fractional Flow Reserve. J Am Coll Cardiol. 2016;68:1181–1191. doi: 10.1016/j.jacc.2016.06.035.
14. Hwang D, Jeon KH, Lee JM. et al. Diagnostic Performance of Resting and Hyperemic Invasive Physiological Indices to Define Myocardial Ischemia: Validation With 13N-Ammonia Positron Emission Tomography. JACC Cardiovasc Interv. 2017;10:751–760. doi: 10.1016/j.jcin.2016.12.015.
15. Jeremias A, Maehara A, Généreux P. et al. Multicenter core laboratory comparison of the instantaneous wave-free ratio and resting Pd/Pa with fractional flow reserve: the RESOLVE study. J Am Coll Cardiol. 2014;63:1253–1261. doi: 10.1016/j.ihj.2018.10.215.
16. Kolh P, Windecker S, Alfonso F. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014;46:517–592. doi: 10.1093/eurheartj/ehu278.
17. Levine GN, Bates ER, Blankenship JC. et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574–651. doi: 10.1002/ccd.24776.
18. Li J, Elrashidi MY, Flammer AJ. et al. Long-term outcomes of fractional flow reserve-guided vs. angiography-guided percutaneous coronary intervention in contemporary practice. Eur Heart J. 2013;34:1375–1383. doi: 10.1093/eurheartj/eht005.
19. Lotfi A, Jeremias A, Fearon WF. et al. Expert consensus statement on the use of fractional flow reserve, intravascular ultrasound, and optical coherence tomography: a consensus statement of the Society of Cardiovascular Angiography and Interventions. Catheter. Cardiovasc. Interv. 2014;83:509–518. doi: 10.1002/ccd.25222.
20. Mangiacapra F, Bressi E, Sticchi A. et al. Fractional flow reserve (FFR) as a guide to treat coronary artery disease. Expert Rev Cardiovasc Therapy. 2018;16:465–477. doi: 10.1080/14779072.2018.1489236.
21. Muller O, Mangiacapra F, Ntalianis A. et al. Long-term follow-up after fractional flow reserve-guided treatment strategy in patients with an isolated proximal left anterior descending coronary artery stenosis. JACC Cardiovasc Interv. 2011;4:1175–1182. doi: 10.1016/j.jcin.2011.09.007.
22. Neumann F-J, Sousa-Uva M, Ahlsson A. et al. A Byrne Jean-Philippe Collet Volkmar Falk Stuart J Head 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40, Issue 2:87–165. doi: 10.1093/eurheartj/ehy394.
23. Patel MR, Calhoon JH, Dehmer GJ. et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2016 Appropriate Use Criteria for Coronary Revascularization in Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2017. 69 (5):570–591. doi: 10.1016/j.jacc.2016.10.034.
24. Patel MR, Calhoon JH, Dehmer GJ. et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2017;69:2212–2241. doi: 10.1007/s12350-017-1070-1.
25. Pijls NH, Van Gelder B, Van der Voort P. et al. Fractional flow reserve. A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. Circulation. 1995;92:3183–3193. doi: 10.1161/01.cir.92.11.3183.
26. Pijls NHJ, van Son JAM, Kirkeeide RL. et al. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation. 1993;87:1354–1367. doi: 10.1161/01.cir.87.4.1354.
27. Rioufol G, Mewton N, Rabilloud M. et al. Functional Testing Underlying Revascularization: The FUTURE Trial. Presented at American Heart Association Scientific Sessions 2016 on November 14, 2016. New Orleans, LA. doi: 10.1358/dof.2016.041.12.2571709.
28. Sen S, Escaned J, Malik I.S. et al. Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis: results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) study. J Am Coll Cardiol. 2012;59:1392–1402. doi: 10.1016/j.jacc.2011.11.006.
29. Shlofmitz E, Jeremias A. FFR in 2017: Current Status in PCI Management https://www.acc.org/latest-in-cardiology/articles/2017/05/25/08/34/ffr-in-2017-current-status-in-pci-management.
30. Smits PC, Abdel-Wahab M, Neumann FJ. et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. New Engl J Med. 2017;376:1234–1244. doi: 10.1056/nejmc1706275.
31. Tonino PA, De Bruyne B, Pijls NH. et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. New Engl J Med. 2009;360:213–224. doi: 10.1056/NEJMoa0807611.
32. Van Belle E, Rioufol G, Pouillot C. et al. Outcome impact of coronary revascularization strategy reclassification with fractional flow reserve at time of diagnostic angiography: insights from a large French multicenter fractional flow reserve registry. Circulation. 2014;129:173–185. doi: 10.1161/circulationaha.113.006646.
33. Vergallo R, Uemura S, Soeda T. et al. Prevalence and Predictors of Multiple Coronary Plaque Ruptures: In Vivo 3-Vessel Optical Coherence Tomography Imaging Study. Arterioscler Thromb Vasc Biol. 2016;36:2229–2238. doi: 10.1161/atvbaha.116.307891.
34. Zimmermann FM, Ferrara A, Johnson NP. et al. Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial. Eur Heart J. 2015;36:3182–3188. doi: 10.1093/eurheartj/ehv452.

[PDF] [Contents]  

  

 

 

Pathogenetic mechanism of stented coronary arteries restenosis and the role of vasculoendothelial growth factor A

M.P. Kopytsya, I.M. Kutya, I.R. Vyshnevska

References  

1. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. Embo J.1999;18:3964-72.

2. Bagyura Z, Kiss L, Berta B, Szilágyi A, Hirschberg K, Széplaki G, Lux A, Szelid Z, Soós P, Merkely B. Association between VEGF Gene Polymorphisms and In-Stent Restenosis after Coronary Intervention Treated with Bare Metal Stent. Dis Markers.2017;7:9548-612. doi: 10.1155/2017/9548612.
3. Bräsen J. H, Kivelä A, Röser K, et al. Angiogenesis, vascular endothelial growth factor and platelet-derived growth factor-BB expression, iron deposition, and oxidation-specific epitopes in stented human coronary arteries. Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21(11):1720–1726. doi: 10.1161/hq1101.098230.
4. Breunis W. B, Biezeveld M. H, Geissler J, Ottenkamp I, Kuipers M, Lam J, Hutchinson A, Welch R, Chanock S. J, Kuijpers T. W. Vascular endothelial growth factor gene haplotypes in Kawasaki disease. Arthritis and Rheumatism. 2006;54(5):1588–1594. doi: 10.1002/art.21811.
5. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001;7:425-9.
6. Cheng G, Chang FJ, Wang Y, You PH, Chen HC, Han WQ, Wang JW, Zhong NE, Min ZQ. Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up. Med Sci Monit. 2019;25:240–247. Published 2019 Jan 8. doi:10.12659/MSM.908692
7. Choi D.H, Kang S.N, Kimetal S.M. Growthfactors-loaded stents modified with hyaluronic acid and heparin for induction of rapid and tight re-endothelialization Colloids and Surfaces B. Biointerfaces. 2016;141:602–610.
8. Dangas G, Claessen B, Caixeta A, Sanidas E.A, Mintz G.S, Mehran R. In-stent restenosis in the drag-eluting stent era. J Am Coll Cardiol. 2010;56(23):1897-1907. doi: 10.1016/j.jacc.2010.07.028
9. Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet 2003;361:247-249. PMID: 12547552 doi: 10.1016/S0140-6736(03)12275-1
10. Gossl M, Herrmann J, Tang H, Versari D, Galili O, Mannheim D, Rajkumar SV, Lerman LO, Lerman A. Prevention of vasa vasorum neovascularization attenuates early neointima formation in experimental hypercholesterolemia. Basic Res Cardiol. 2009;104:695-706.
11. Grosskreutz CL, Anand-Apte B, Dupláa C, Quinn TP, Terman BI, Zetter B, D'Amore PA.Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. Microvascular Research. 1999;58(2):128–136. doi: 10.1006/mvre.1999.2171
12. Hoeben A, Landuyt B, Martin S. Highley, Wildiers H, Allan T. Van Oosterom, Ernst A, De Bruijn. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 2004;56:549–580. doi: 10.1124/pr.56.4.3.
13. Hutter R, Carrick F.E, Valdiviezoetal C. Vascularendothe-lial growth factor regulates reendothelialization and neointima formationinamousemodelofarterialinjury. Circulation. 2004;110(16):2430–5. pmid:15477421
14. Kastrati A, Koch W, Berger PB, Mehilli J, Stephenson K, Neumann F, Beckerath N, Bo¨ttiger C, Duff G, Scho¨mig A. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. Journal of the American College of Cardiology. 2000;36(7):2168–2173. doi: 10.1016/S0735-1097(00)01014-7.
15. Katsaros KM, Kastl SP, Krychtiuk KA, Hutter R, Zorn G, Maurer G, Huber K, Wojta J, Christ G, Speidl WS..An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents. EuroIntervention. 2014;10(2):224–30. pmid:24168783 doi: 10.4244/EIJV10I2A36
16. Kazmierczak E, Grajek S, Kowal J, Chmara E, Grygier M, Pyda M, Bogdanski P, Cieslewicz A, Jablecka A. Prognostic usefulness of IL-6 and VEGF for the occurrence of changes in coronary arteries of patients with stable angina and implanted stents. European Review for Medical and Pharmacological Sciences. 2014;18(15):2169-2175.
17. Keavney B. Outcome following percutaneous coronary intervention: not, so far, in our genes. Heart. 2003;89(3):247–248. doi: 10.1136/heart.89.3.247.
18. Khurana R, Zhuang Z, Bhardwaj S, Murakami M, De Muinck E, Yla-Herttuala S, Ferrara N, Martin JF, Zachary I, Simons M. Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation. 2004;110(16):2436–43. pmid:15477408
19. Koch W, Böttiger C, Mehilli J, Beckerath N, Neumann FJ, Schömig A, Kastrati A. Association of a CD18 gene polymorphism with a reduced risk of restenosis after coronary stenting. American Journal of Cardiology. 2001;88(10):1120–1124. doi: 10.1016/S0002-9149(01)02045-8.
20. Kollum M, Kaiser S, Kinscherf R, Metz J, Kübler W, Hehrlein C. Apoptosis after stent implantation compared with balloon angioplasty in rabbits. Role of macrophages. Arterioscler Thromb Vasc Biol. 1997;17(11):2383–8. pmid:9409205
21. Leopold JA. Neoatherosclerosis: another consequence of endothelial dysfunction?Circ Cardiovasc Interv. 2014;7(5):635-7. doi: 10.1161/circinterventions.114.001994.
22. Li D, Zhang C, Song F, Lubenec I, Tian Y, Song Q.H. VEGF regulates FGF-2 and TGF-1 expression in injury endothelial cells and mediates smooth muscle cells proliferation and migration, Microvascular Research.2009;77:(2):134–142.
23. Ohtani K, Egashira K, Hiasa K, Zhao Q, Kitamoto S, Ishibashi M, Usui M, Inoue S, Yonemitsu Y, Sueishi K, Sata M, Shibuya M, Sunagawa K. Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells. Circulation. 2004;110(16):2444–52. pmid:15477409
24. Osadnik T, Strzelczyk J. K, Reguła R, Bujak K, Fronczek M, Gonera M, Gawlita M, Wasilewski J, Lekston A, Kurek A, Gierlotka M, Trzeciak P, Hawranek M, Ostrowska Z, Wiczkowski A, Poloński L, Gąsior M. The relationships between polymorphisms in genes encoding the growth factors TGF-β1, PDGFB, EGF, bFGF and VEGF-A and the restenosis process in patients with stable coronary artery disease treated with bare metal stent. Plos one. 2016;11(3) doi: 10.1371/journal.pone.0150500.e150500
25. Ramos C, Napoleao P, Selas M. Freixo C, Crespo MM, Carmo MM, Ferreira R, Pinheiro T. Prognostic value of vegf in patients submitted to percutaneous coronary intervention. Disease Markers.2014; (7). ID 135357.
26. Shiojima I, Walsh K. The role of vascular endothelial growth factor in restenosis: the controversy continues. Circulation. 2004;110:2283-6
27. Verschuren JJW, Trompet S, Postmus I, Lourdes Sampietro M, Heijmans BT, Houwing-Duistermaat J, Slagboom E, Jukema JW. Systematic testing of literature reported genetic variation associated with coronary restenosis: Results of The gender Study. PLOS ONE. 2012;7(8) doi: 10.1371/journal.pone.0042401.e42401
28. . Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: Correlation with variation in VEGF protein production. Cytokine 2000;12:1232–1235. doi: 10.1006/cyto.2000.0692
29. Weintraub WS. The pathophysiology and burden of restenosis. Am J Cardiol. 2007 Sep;100(5A):3K–9K. pmid:17719351
30. Wu X, Zhao Y, Tang C, Yin T, Du R, Tian J, Huang J, Gregersen H, Wang G. Re-endothelialization study on endovascular stents seeded by endothelial cells through up- or downregulation of VEGF. ACS Appl. Mater. Interfaces. 2016;8:7578–7589. doi: 10.1021/acsami.6b00152
31. Xuming Dai, Szymon Wiernek, James P Evans, Marschall S Runge. Genetics of coronary artery disease and myocardial infarction. World J Cardiol 2016;26;8(1):1–23. doi: 10.4330/wjc.v8.i1.1
32. Yang J, Zeng Y, Zhang C, Chen YX, Yang Z, Li Y, Leng X, Kong D, Wei XQ, Sun HF, Song CX. The prevention of restenosis in vivo with a VEGF gene and paclitaxel co-eluting stent. Biomaterials. 2013;34(6):1635-43. doi: 10.1016/j.biomaterials.2012.11.006.
33. Yin J, Shen L, Ji M, Wu Y, Cai S, Chen J, Yao Z, Ge1 J. Inverse Relationship between Serum VEGF Levels and Late In-Stent Restenosis of Drug-Eluting Stents. Biomed Res Int. 2017;(6): Article ID 8730271. doi: 10.1155/2017/8730271.
34. Yu Y, Gao Y, Qin J, Kuang CY, Song MB, Yu SY, Cui B, Chen JF, Huang L. CCN1 promotes the differentiation of endothe -lial progenitor cells and reendothelialization in the early phase after vascular injury. Basic Res Cardiol. 2010;105:713–24.

[PDF] [Contents]  

  

 

 

Long-term results of invasive and non-invasive treatment strategies in the elderly patients with acute coronary syndrome

R.R. Komorovsky

References  

1.Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC. Jr.; American College of Cardiology; American Heart Association; Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44:671-719. doi: 10.1016/j.jacc2004.07.002

2.Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos LA, Anderson HV, DeLucca PT, Mahoney EM, Murphy SA, Braunwald E. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndrome. Ann Intern Med. 2004;141(3):186-195. doi: 10.7326/0003-4819-141-3-200408030-00007

3.Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine C.J, Schaeffer JW, Smith EE. 3rd, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russel RO, Smith SC. Jr. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2000;36:970-1062. doi: 10.1016/S0735-1097(00)00889-5

4.Delvin G. Women and elderly: subgroups under-represented in clinical trials. Curr Opin Cardiol. 2010;25:335-339. doi: 10.1097/HCO.0b013e328338bcab

5.Elbadawi A, Elgendy IY, Ha LD, Saad M, Mahmoud K, Ogunbayo GO, Kumfa P, Rangasetty UC, Gilani S. National trends of percutaneous coronary intervention in patients ≥70 years of age. Am J Cardiol. 2019;123(4):701-703. doi: 10.1016/j.amjcard.2018.11.053

6.García-Blas S, Bonanad C, Sanchis J. Invasive strategy in elderly patients with acute coronary syndrome in 2018: close to truth. J Geriatr Cardiol. 2019;16:114-120. doi: 10.11909/j.issn.1671-5411.2019.02.004

7.Hordijk-Trion M, Lenzen M, Wijns W, de Jaegere P, Simoons ML, Scholte op Reimer WJ, Bertrand ME, Mercado N, Boersma E; EHS-CR Investigators. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart  J. 2006;27(6):671-678. doi: 10.1093/eurheartj/ehi731.

8.Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P, ESC Scientific Document Group. 2017 Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177. doi: 10.1093/eurheartj/ehx393

9.Lattuca B, Kerneis M, Zeitouni M, Cayla G, Guedeney P, Collet J-P, Montalescot G, Silvain J. Elderly patients with ST-segment elevation myocardial infarction: a patient-centered approach. Drugs Aging 2019 (Epub 2019 Apr 5). doi: 10.1007/s40266-019-00663-y

10.Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001;286(6):708-713. doi: 10.1001/jama.286.6.708

11.Leng WX, Yang J, Li W, Wang Y, Yang YL.; DEAR-OLD investigators. Rationale and design of the DEAR-OLD trial: randomized evaluation of routinely deferred versus EARly invasive strategy in elderly patients of 75 years or OLDer with non-ST-elevation myocardial infarction. Am Heart J. 2018;196:65-73. doi: 10.1016/j.ahj.2017.10.022

12.Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne R, Collet J-P, Falk V, Head S.J, Jüni P, Kastrati A, Koller A, Kristensen S.D, Niebauer J, Richter D.J, Seferović PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO, ESC Scientific Document Group. 2018 ESC/EACTS  Guidelines on myocardial revascularization: The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2019;40(2):87-165. doi: 10.1093/eurheartj/ehy394

13.Pfisterer M, Buser P, Osswald S, Allemann U, Amann W, Anghern W, Eeckhout E, Erne P, Estlinbaum W, Kuster G, Moccetti T, Naegeli B, Rickenbacher P; Trial of Invasive versus Medical therapy in Elderly patients (TIME) investigators. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA 2003;289(9):1117-1123. doi: 10.1001/jama.289.9.1117

14.Rich MV, Chyun DA, Skolnick AH, Alexander KP, Forman DE, Kitzman DW, Maurer MS, McClurken JB, Resnick BM, Shen WK, Tirschwell DL. Knowledge gaps in cardiovascular care of the older adult population: a scientific statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society. J Am Coll Cardiol. 2016;67(20):2419-2440. doi: 10.1016/j.jacc.2016.03.004

15.Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancelotti P, Landmesser U, Mehili J, Mukherjee D, Storey RF, Windecker S, ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. doi: 10.1093/eurheartj/ehv320

16.Sanchis J, Ariza-Solé A, Abu-Assi E, Alegre O, Alfonso F, Barrabés JA, Baz J.A, Carol A, Díez Villanueva P, García del Blanco B, Elízaga J, Fernandez E,  García del Edigo A, García Picard J, Gómez Blázquez I, Gómez Hospital JA, Hernández-Antolín R, Libre C, Marín F, Martí Sánchez D, Martín R, Martínez Sellés M, Miñana G, Morales Gallardo MJ, Núñez J, Pérez de Prado A, Pinar E, Sanmartín M, Sionis A, Villa A, Marrugat J, Bueno H. Invasive versus conservative strategy in frail patients with NSTEMI: the MOSCA-FRAIL clinical trial study design. Rev Esp Cardiol. 2019;72:154-159. doi: 10.1016/j.rec2018.02.007

17.Sanchis J, Soler M, Núñez J, Ruiz V, Bonanad C, Formiga F, Valero E, Martínez-Sellés M, Marín F, Ruescas A, García-Blas S, Miñana G, Abu-Assi E, Bueno H, Ariza-Solé A. Comorbidity assessment for mortality risk in elderly patients with acute coronary syndrome. Eur J Intern Med. 2019;62:48-53. doi: 10.1016/j.ejim.2019.01.018

18.Savonitto S, Cavallini C, Petronio AS, Murena E, Antonicelli R, Sacco A, Steffenino G, Bonechi F, Mossuti E, Manari A, Tolaro S, Toso A, Daniotti A, Piscione F, Morici N, Cesana BM, Jori MC, De Servi S; Italian Elderly ACS Trial Investigators. Early aggressive versus initially conservative treatment in elderly patients with non-ST-segment elevation acute coronary syndrome: a randomized controlled trial. JACC Cardiovasc Interv. 2012;5(9):906-916. doi: 10.1016/j.jcin.2012.06.008

19.Tegn N, Abdelnoor M, Aaberge L, Endresen K, Smith P, Aakhus S, Gjertsen E, Dahl-Hofseth O, Ranhoff AH, Gullestad L, Bendz B; After Eighty study investigators. Invasive versus conservative strategy in patients aged after 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet 2016;387:1057-1065. doi: 10.1016/S0140-6736(15)01166-6

20.Vincent L, Martínez-Sélles M. Frailty and acute coronary syndrome: does gender matter? J Geriatr Cardiol. 2019;16:138-144. doi: 10.11909/j.issn.1671-5411.2019.02.007

[PDF] [Contents]  

  

 

 

Predictors of the occurrence of cardiovascular events in patients with atrial flutter during long-term follow-up

A.V. Aker, U.P. Chernyaga-Royko, N.S. Pavlyk, O.J. Zharinov

References  

1.Zalizna YuI, Mikhalev KO, Zharinov OJ. Predictors of arrhythmia recurrence after the first episode of atrial fibrillation during 6-months follow-up. Ukr Cardiol J. 2017;6:68–78. (in Ukr.).

2.Al-Kawaz M, Omran S, Parikh N, Elkind M, Soliman EZ, Kamel H. Comparative risks of ischemic stroke in atrial flutter versus atrial fibrillation. J Stroke Cerebrovasc Dis. 2018;27(4):839–844. doi:10.1016/j.jstrokecerebrovasdis.2017.10.025.

3.Brembilla-Perrot В, Ferreira J, Manenti V, Sellal JM, Olivier A, Villemin T, Beurrier D, De Chillou C, Louis P, Brembilla A, Juillière Y, Girerd N. Predictors and prognostic significance of tachycardiomyopathy: insights from a cohort of 1269 patients undergoing atrial flutter ablation. Eur J Heart Fail. 2016;18(4):394–401. doi: 10.1002/ejhf.482.

4.Brembilla-Perrot B, Girerd N, Sella JM, Olivier A, Manenti V, Villemin T, Beurrier D, de Chillou C, Louis P, Selton O, de la Chaise AT. Risk of atrial fibrillation after atrial flutter ablation: impact of AF history, gender, and antiarrhythmic drug medication. J Cardiovasc Electrophysiol. 2014;25(8):813–820. doi: 10.1111/jce.12413.

5.Chao Tze-Fan, Fauchier L. Stroke prevention in patients with atrial flutter. Europace. 2019;21(2):186–187. doi: 10.1093/europace/euy197.

6.Chen Y-L, Lin Y-S, Wang H-T, Liu WH, Chen HC, Chen MC. Clinical outcomes of solitary atrial flutter patients using anticoagulation therapy: a national cohort study. Europace. 2019;21:313–321. doi:10.1093/europace/euy181.

7.De Loma-Osorio F, Diaz-Infante E, Gallego M. Spanish Catheter Ablation Registry. 12th Official Report of the Spanish Society of Cardiology Working Group on Electrophysiology and Arrhythmias (2012). Rev Esp Cardiol (Engl. Ed.). 2013;66:983–992. doi: 10.1016/j.rec.2013.08.002.

8.Glover B, Chen J, Hong K, Boveda S, Baranchuk A, Haugaa KH, Dorian P, Potpara TS, Crystal E, Mitchell B, Tilz R, Leong-Sit P, Dagres N. Catheter ablation for atrial flutter: a survey by the European Heart Rhythm Association and Canadian Heart Rhythm Society. Europace. 2016;18(12):1880–1885. doi: 10.1093/europace/euw402.

9.Granada J, Uribe W, Chyou P, Maassen K, Vierkant R, Smith PN, Hayes J, Eaker E, Vidaillet H. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol. 2000;36:2242–2246. doi: 10.1016/s0735-1097(00)00982-7.

10.Huxley R, Lopez F, Folsom A, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123:1501–1508. doi: 10.1161/circulationaha.110.009035.

11.Kafkas N, Patsilinakos S, Mertzanos G, Papageorgiou KI, Chaveles JI, Dagadaki OK, Kelesidis KM. Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. Intern J Cardiology. 2007;118(3):321–325. doi: 10.1016/j.ijcard.2006.07.017.

12.Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962. doi:10.1093/ejcts/ezw313.

13.Lin Y, Chen T, Chi C, Lin MS, Tung TH, Liu CH, Chen YL, Chen MC. Different Implications of Heart Failure, Ischemic Stroke, and Mortality Between Nonvalvular Atrial Fibrillation and Atrial Flutter-a View From a National Cohort Study. J Am Heart Assoc. 2017;6(7):2047–9980. doi: 10.1161/JAHA.117.006406.

14.Luchsinger J, Steinberg J. Resolution of cardiomyopathy after ablation of atrial flutter. J Am Coll Cardiol. 1988;32(1):205–210. doi:10.1016/s0735-1097(98)00183-1.

15.Page R, Joglar J, Caldwell M. et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. J Am Coll Cardiol. 2016;67(13):1575–1623. doi:10.1161/CIR.0000000000000311.

16.Pérez FJ, Schubert CM, Parvez B, Pathak V, Ellenbogen KA, Wood MA. Long-term outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta-analysis. Circ Arrhythm Electrophysiol. 2009;2(4):393–401. doi:10.1161/circep.109.871665.

17.Peyrol M, Sbragia P, Bonello L, Lévy S, Paganelli F. Characteristics of isolated atrial flutter versus atrial flutter combined with atrial fibrillation. Arch Cardiovasc Diseases. 2011;104(10):530–535. doi: 10.1016/j.acvd.2011.07.003.

18.Rahman F, Wang N, Yin X, Ellinor PT, Lubitz SA, LeLorier PA, McManus DD, Sullivan LM, Seshadri S, Vasan RS, Benjamin EJ, Magnani JW. Atrial flutter: Clinical risk factors and adverse outcomes in the Framingham Heart Study. Heart Rhythm. 2016;13(1):233–240. doi: 10.1016/j.hrthm.2015.07.031. 

19.Savarese G, Lund L. Global Public Health Burden Of Heart Failure. Cardiac Failure Review. 2017;3(1):7–11. doi: 10.15420/cfr.2016:25:2.

20.Vadmann H, Gorst-Rasmussen A, Hjortshøj SP, Riahi S, Lip GYH, Larsen TB. Death and thrombo-embolic risk after ablation of atrial flutter compared with atrial fibrillation: a nationwide cohort study. Europace. 2017;19(5):838–842. doi:10.1093/europace/euw107.

[PDF] [Contents]  

  

 

 

 

Tactics of the treatment of left atrial angiosarcoma

R.M. Vitovskyi, V.V. Isaіenko, D.М. Dyadyun, O.A. Pishchurin, V.F. Onishchenko, Ya.R. Ivanov, O.V. Kupchinskyi 

References   

1. Burke A, Tavora F. The 2015 WHO Classification of tumors of the heart and pericardium. J Thoracic Oncology. 2016;11(4):441–452. doi: 10.1016/j.jtho.2015.11.009.
2. Hudzik B, Miszalski-Jamka K, Glowacki J. et al. Malignant tumors of the heart. Cancer Epidemiol. 2015;39(5):665–672. doi: 10.1016/j.canep.2015.07.007.
3. Isogai T, Yasunaga H, Matsui H. et al. Factors affecting in-hospital mortality and likelihood of undergoing surgical resection in patients with primary cardiac tumors. J Cardiology. 2017;69:287–292. doi: 10.1016/j.jjcc.2016.05.008.
4. Lestuzzi C, De Paoli A, Baresic T. et al. Malignant cardiac tumors: diagnosis and treatment. Future Cardiol. 2015;11(4):485–500. doi: 10.2217/fca.15.10.
5. Mkalaluh S, Szczechowicz M, Torabi S. et al. Surgical treatment of cardiac tumors: insights from an 18-year single-center analysis. Med Sci Monit. 2017;31(23):6201–6209. doi: 10.12659/msm.905451.
6. Oliveira GH, Al-Kindi SG. et al. Characteristics and Survival of Malignant Cardiac Tumors: A 40-Year Analysis of 500 Patients. Circulation. 2015;132:2395–2402. doi: 10.1161/circulationaha.115.016418.
7. Truong J, Yan A.T, Cramarossa G. et al. Chemotherapy-induced cardiotoxicity: detection, prevention and management. Can J Cardiology. 2014;30:869–878. doi: 10.1016/j.cjca.2014.04.029.
8. Yanagawa B, Mazine A, Chan EY. et al. Surgery for tumors of the heart. Semin Thorac Cardiovasc Surg. 2018;8, 30(4):385–397. doi: 10.1053/j.semtcvs.2018.09.001
9. Yin L, He D, Shen H. et al. Surgical treatment of cardiac tumors: a 5-year experience from a single cardiac center. J Thorac Dis. 2016;8(5):911–919. doi: 10.21037/jtd.2016.03.87.

[PDF] [Contents]  

  

 

 

Case of surgical treatment of ascending aorta and aortic arch aneurysm in a patient with unclassified connective tissue disease

B.M. Todurov, A.Y. Shkandala, O.V. Zelenchuk, M.F. Rotar, N.S. Gnoyanko 

References  

1. Hereditary connective tissue diseases in cardiology. Diagnosis and treatment. Russ Cardiol J. 2013;1(99) Suppl 1. (In Russ.).
2. Bokeria L, Gudkova R, Arakelyan V. Surgical treatment of aneurysms of the thoracic and abdominal aorta in Russia. Thoracic and Cardiovascular Surgery. 2017;59(3):181–190.
3. Booher AM, Eagle KA. Diagnosis and management issues in thoracic aortic aneurysm. Amer Heart J. 2011;1(162):38–46. doi: 10.1016/j.ahj.2011.04.010.
4. Gilbert R, Upchurch Jr, Enrique Criado. Aortic Aneurysms Pathogenesis and Treatment. Humana Press, A part of Springer Science + Business Media, LCC 2009: 337–338, 341, 343, 344. doi: 10.1007/978-1-60327-204-9.
5. Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, Hilhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, Pyeritz RE, Sponseller PD, Wordsworth P, De Paepe AM. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010; 47:476–485. doi: 10.1136/jmg.2009.072785.

[PDF] [Contents]  

  

 

 

The first clinical case of the left-ventricular electrode implantation with active fixation for the purpose of cardiac resynchronization therapy in Ukraine

V.V. Boiko, S.V. Rybchynskyi, D.O. Lopin, D.E. Volkov

References   

1. Bontempi L., Vassanelli F., Ashofair N, Inama L, Mariggiò D, Cerini M, Curnis A. The Novel Active Fixation Coronary Sinus Lead: Efficacy and Safety of Transvenous Extraction Procedure. Europace. 2015;18(2):301–303. doi: 10.1093/europace/euv227.
2. Cazeau S, Ritter P, Bakdach S, Lazarus A, Limousin M, Henao L, Mundler O, Daubert JC, Mugica J. Four chamber pacing in dilated cardiomyopathy. Pacing Clin Electrophysiol. 1994;17(11 Pt 2):1974–9.
3. Daubert C, Behar N, Martins RP, Mabo P, Leclercq C. Avoiding non-responders to cardiac resynchronization therapy: a practical guide. European Heart Journal [Internet]. Oxford University Press (OUP); 2016;ehw270. doi: 10.1093/eurheartj/ehw270.
4. Gamble JHP, Herring N, Ginks M, Rajappan K, Bashir Y, Betts TR. Procedural Success of Left Ventricular Lead Placement for Cardiac Resynchronization Therapy. JACC: Clinical Electrophysiology [Internet]. Elsevier BV. 2016;2(1):69–77. doi: 10.1016/j.jacep.2015.08.009.
5. Giannola G, Torcivia R, Airò Farulla R, Heynens J. Overcoming an Impossible Anatomy with a Novel Left Ventricular Active Fixation Lead in the Coronary Sinus: A Case Report. HeartRhythm Case Reports. 2015;1(3):130–132. doi: 10.1016/j.hrcr.2015.01.006.
6. Seferović PM. ESC/HFA Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2016. Journal of Cardiac Failure [Internet]. Elsevier BV; 2017 Oct;23(10):S7. doi: 10.1016/j.cardfail.2017.08.005.
7. Yee R, Gadler F, Hussin A, Bin Omar R, Khaykin Y, Verma A, Lazeroms M, Hine DS, Marquard KR. Novel Active Fixation Mechanism Permits Precise Placement of a Left Ventricular Lead: Early Results from a Multicenter Clinical Study. Heart Rhythm. 2014;11(7):1150–1155. doi: 10.1016/j.hrthm.2014.04.020.
8. Ziaeian B, Fonarow G. Epidemiology and aetiology of heart failure. Nature Reviews Cardiology. 2016;13(6):368–378. doi: 10.1038/nrcardio.2016.25.
9. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal [Internet]. Oxford University Press (OUP). 2013.24;34(29):2281–2329. doi: 10.1093/eurheartj/eht150.

[PDF] [Contents]  

  

 

 

Plastics of the left ventricle aneurysm with minimally invasive multivessel coronary artery bypass grafting

V.M. Demianenko, O.D. Babliak, D.Ye. Babliak, O.S. Stohov, E.A. Melnyk, K.A. Revenko, L.V. Pidgayna

References   

1. Babliak OD, Demyanenko VM. Miniinvasive multivessel coronary grafting througt left anterior thoracotomy. Heart and vessels. 2018;1(61):65–69 (in Ukr.)
2. Babliak OD, Demyanenko VM. Minimally invasive multivasel coronary artery bypass grafting: analysis of early results and mastery of technique. Herald Cardiovascular Surgery. 2018;4(33):18–21 (in Ukr.)
3. Cooley DA, Collins HA, Morris GC, Chapman DW. Ventricular aneurysm after myocardial infarction: Surgical excision with the use of temporary cardiopulmonary bypass. JAMA. 1958;167:557.
4. Delewi R, Zijlstra F, Piek JJ. Left ventricular thrombus formation after acute myocardial infarction. Heart. 2012;98:1743–1749. doi: 10.1136/heartjnl-2012-301962.
5. Dor V, Di Donato M, Sabatier M. et al. Left ventricular reconstruction by endoventricular circular patch plasty repair: A 17-year experience. Seminars in Thoracic and Cardiovascular Surgery. 2001;13(4):435–447. doi: 10.1053/stcs.2001.29966.
6. Kirklin JW, Barratt-Boyes B. Cardiac Surgery. Left ventricular aneurysm. Eds. C. Livingstone. N.Y, 1993:383.
7. Likoff W, Bailey CP. Ventriculoplasty-excision of myocardial aneurysm. JAMA. 1955;158:915.
8. Rosen SD. Left ventricular aneurysm formation after acute myocardial infarction. Intern. J. Cardiology. 2002;82(1):14–16. doi: 10.1016/s0167-5273(01)00597-6.
9. Stoodley PW, Richards DAB. Anatomical and physiological complications related to left ventricular apical aneurysm. Sonography Wiley. 2016;16, 4(2):70–75. doi: 10.1002/sono.12095.

[PDF] [Contents]